Caricamento...
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
BACKGROUND: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore m...
Salvato in:
| Pubblicato in: | Breast Cancer Res |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5339994/ https://ncbi.nlm.nih.gov/pubmed/28264701 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0815-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|